RICFY (Recordati SpA) Gross-Profit-to-Asset % : 37.22% (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Recordati SpA Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Recordati SpA's annualized Gross Profit for the quarter that ended in Sep. 2024 was $1,710 Mil. Recordati SpA's average Total Assets over the quarter that ended in Sep. 2024 was $4,594 Mil. Therefore, Recordati SpA's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 was 37.22%.

Recordati SpA Gross-Profit-to-Asset % Historical Data

The historical data trend for Recordati SpA's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recordati SpA Gross-Profit-to-Asset % Chart

Recordati SpA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

41.62

39.49

40.18

36.74

35.16

Recordati SpA Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															31.36	34.20	39.10	36.25	37.22

Competitive Comparison of Recordati SpA's Gross-Profit-to-Asset %

For the Drug Manufacturers - General subindustry, Recordati SpA's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Recordati SpA's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Recordati SpA's Gross-Profit-to-Asset % falls into.

Recordati SpA Gross-Profit-to-Asset % Calculation

Recordati SpA's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	1551.389	/	( (4236.041	+	4589.02)	/ 2 )
	=	1551.389	/	4412.5305
	=	35.16 %

Recordati SpA's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	1709.764	/	( (4521.759	+	4665.457)	/ 2 )
	=	1709.764	/	4593.608
	=	37.22 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Recordati SpA Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Recordati SpA's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Recordati SpA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Recordati SpA (OTCPK:RICFY) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

REC:Italy RECm:UK 0KBS:UK RER1:Germany RER1:Germany REC:Austria

Address

Via Matteo Civitali 1, MIlan, ITA, 20148

Website

https://www.recordati.com

Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment which includes the production of active ingredients.